[1]王辰潇.心脉通胶囊联合培哚普利对冠心病患者血清IL-6、MMP-9和TNF-α水平的影响[J].医学信息,2021,34(07):150-152,156.[doi:10.3969/j.issn.1006-1959.2021.07.042]
　WANG Chen-xiao.Effect of Xinmaitong Capsule Combined with Perindopril on Serum IL-6,MMP-9 and TNF-α Levels in Patients with Coronary Heart Disease[J].Medical Information,2021,34(07):150-152,156.[doi:10.3969/j.issn.1006-1959.2021.07.042]
点击复制

心脉通胶囊联合培哚普利对冠心病患者血清IL-6、MMP-9和TNF-α水平的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年07期
页码:
150-152,156
栏目:
药物与临床
出版日期:
2021-04-01

文章信息/Info

Title:
Effect of Xinmaitong Capsule Combined with Perindopril on Serum IL-6,MMP-9 and TNF-α Levels in Patients with Coronary Heart Disease
文章编号:
1006-1959（2021）07-0150-04
作者:
王辰潇
（佳木斯市中心医院药剂科，黑龙江 佳木斯 154002）
Author(s):
WANG Chen-xiao
(Department of Pharmacy,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
心脉通胶囊; 培哚普利; 冠心病; 白介素-6; 基质金属蛋白酶-9; 肿瘤坏死因子-α
Keywords:
Xinmaitong capsule; Perindopril; Coronary heart disease; Interleukin-6;  Matrix metalloproteinase-9; Tumor necrosis factor-α
分类号:
R541.4
DOI:
10.3969/j.issn.1006-1959.2021.07.042
文献标志码:
A
摘要:
目的 研究心脉通胶囊联合培哚普利对冠心病患者血清白介素-6（IL-6）、基质金属蛋白酶-9（MMP-9）和肿瘤坏死因子-α（TNF-α）水平的影响。方法 选择2017年1月~2019年12月我院收治的80例冠心病患者，随机分为两组，每组40例。对照组口服培哚普利，观察组在对照组基础上，联合心脉通胶囊。比较两组临床疗效、血清水平（MMP-9、IL-6、TNF-α）、血液流变学指标（全血比黏度、纤维蛋白原水平、血浆比黏度、血细胞比容、全血还原黏度）、心功能指标（LVEF、CO、LVESD、LVEDD）。结果 观察组有效率高于对照组，差异有统计学意义（P＜0.05）；两组血清IL-6、MMP-9和TNF-α水平均降低，且观察组血清MMP-9、IL-6和TNF-α水平低于对照组，差异有统计学意义（P＜0.05）；两组全血比黏度、纤维蛋白原水平、血浆比黏度、血细胞比容、全血还原黏度均降低，且观察组低于对照组，差异有统计学意义（P＜0.05）；两组LVEF和CO升高，LVESD和LVEDD降低，且观察组的LVEF、CO高于对照组，LVESD和LVEDD低于对照组，差异有统计学意义（P＜0.05）。结论 心脉通胶囊联合培哚普利能改善冠心病患者的血液流变学和心功能，其机制可能与降低血清IL-6、MMP-9和TNF-α水平有关。
Abstract:
Objective To study the effect of Xinmaitong capsule combined with perindopril on serum interleukin-6 (IL-6), matrix metalloproteinase-9 (MMP-9) and tumor necrosis factor-α (TNF-α) levels in patients with coronary heart disease influences.Methods 80 patients with coronary heart disease admitted to our hospital from January 2017 to December 2019 were randomly divided into two groups with 40 cases in each group.The control group was taken orally with perindopril, and the observation group was combined with Xinmaitong capsule on the basis of the control group. To compare the clinical efficacy, serum levels (MMP-9, IL-6, TNF-α), hemorheological indexes (whole blood specific viscosity, fibrinogen level, plasma specific viscosity, hematocrit, whole blood reduced viscosity) between the two groups ), cardiac function indicators (LVEF, CO, LVESD, LVEDD).Results The effective rate of the observation group was higher than that of the control group,the difference was statistically significant (P＜0.05);The levels of serum IL-6, MMP-9 and TNF-α in the two groups decreased, and the levels of serum MMP-9, IL-6 and TNF-α in the observation group were lower than those in the control group, the difference was statistically significant (P＜0.05);The two groups of whole blood specific viscosity, fibrinogen level, plasma specific viscosity, hematocrit, and whole blood reduced viscosity all decreased, and the observation group was lower than the control group, the difference was statistically significant (P＜0.05);The two groups of LVEF and CO increased, LVESD and LVEDD decreased, and the observation group LVEF, CO were higher than the control group, LVESD and LVEDD lower than the control group, the difference was statistically significant (P＜0.05).Conclusion Xinmaitong capsule combined with perindopril can improve the hemorheology and cardiac function of patients with coronary heart disease. The mechanism may be related to the reduction of serum IL-6, MMP-9 and TNF-α levels.

参考文献/References:

[1]易德茂,张娟,徐冬梅.阿托伐他汀联合曲美他嗪对冠心病患者心功能、氧化应激及炎症因子的影响[J].海南医学院学报,2017,23(5):631-634. [2]姚立军,陈弹.瑞舒伐他汀与阿托伐他汀对冠心病患者血脂、动脉粥样硬化程度和血管内皮舒张功能的疗效对比[J].中国药房,2017,28(35):4963-4966. [3]姚朝阳.美托洛尔联合曲美他嗪治疗冠心病合并心衰的疗效及对病人生存质量的影响[J].中西医结合心脑血管病杂志,2017,15(10):1213-1215. [4]李广运.培哚普利联合瑞舒伐他汀治疗冠心病的疗效及对血管内皮功能与血小板活化功能的影响[J].中西医结合心脑血管病杂志,2018,16(1):70-73. [5]何晓全,刘梅林.中国冠心病防治策略[J].中国全科医学,2015,18(2):239-240. [6]胡元会,贾秋蕾,孟昊,等.冠心病不稳定型心绞痛患者血瘀证与外周血血小板微粒膜蛋白表达的相关性[J].中医杂志,2017,58(4):321-324. [7]刘伟,王妮.盐酸川芎嗪注射液联合阿司匹林和阿托伐他汀治疗冠心病心绞痛的临床研究[J].现代药物与临床,2017,32(4):602-607. [8]韩会来,秘嘉伟,段丽丽,等.阿托伐他汀联合曲美他嗪对冠心病NT-proBNP、hs-CRP、Fib及心脏功能的影响探析[J].临床检验杂志(电子版),2017,6(4):727-727. [9]潘嘉西,章敏学,郑巨克,等.通心络胶囊联合阿托伐他汀与单用阿托伐他汀对冠心病患者血脂、炎症因子水平的影响比较[J].中华全科医学,2017,15(3):452-453,478. [10]张转利,高莉.阿托伐他汀联合通心络胶囊治疗冠心病伴发高脂血症的临床效果[J]. 临床医学研究与实践,2020,5(24):152-154. [11]宋登鹏,韩安艳.不同剂量培哚普利在冠心病治疗中对循环血内皮祖细胞水平及血管内皮功能的影响[J].临床合理用药杂志,2019,12(11):40-41. [12]黄莺.麝香保心丸联合曲美他嗪对老年冠心病合并心力衰竭患者血管内皮功能及血浆脑钠肽的影响[J].湖北中医药大学学报,2017,19(1):22-25. [13]齐欣,郭书文,陈剑明,等.益气活血法联合酒石酸美托洛尔治疗冠心病心律失常的临床研究[J].中华中医药学刊,2017,35(2):279-282. [14]卢晓,王凤田,刘向前.益气养阴温心汤联合酒石酸美托洛尔治疗冠心病临床研究[J].实用中医药杂志,2020,328(5):108-109. [15]冷德生,高恩宇,李富震,等.中医药治疗冠心病心绞痛的研究进展[J].中医药信息,2017,34(4):119-123. [16]丁丽.心脉通胶囊联合阿托伐他汀治疗冠心病患者疗效及对血压、血脂及血液流变学的影响[J].现代中西医结合杂志,2019,28(7):75-78. [17]徐华,陈佳,梁英杰,等.冠心舒通胶囊联合阿托伐他汀钙对颈动脉粥样硬化患者血脂及超敏C反应蛋白的影响[J].辽宁中医杂志,2018,45(10):2116-2118. [18]陈学彬,宁小康.麝香保心丸对老年冠心病合并颈动脉粥样硬化斑块患者血清hs-CRP、VEGF、MMP-9水平及血脂的影响[J].陕西中医,2017,38(4):427-429. [19]王保军,王康琪.麝香保心丸联合瑞舒伐他汀对老年颈动脉易损斑块的干预研究[J].中国实用医刊,2018,45(12):116-119.

更新日期/Last Update: 1900-01-01